Indeed, in a pre-clinical model using cell line in vivo assays, it was demonstrated that EGFR promotes the survival of PC-circulating tumor cells, while ERBB2 supports cancer cell growth in bones by promoting the RANK signaling pathway [40]. Here, TNFRSF11A is linked to neoplasm.